Dyadic International Inc.

Charles W. Kling IV has been our Vice President, Sales, Enzymes since January 2007. Prior to that he served as our Vice President of Sales and Marketing - Enzymes from July 2005 through December 2006. Prior to joining us, Mr. Kling served as Group Manager of Hercules, Inc.'s Pulp & Paper division, with full P&L responsibility and management of staff of over 60 people, from 1998 to 2005. Prior to Hercules, from 1990 to 1998, Mr. Kling served as Global Director, Technical Marketing for BetzDearborn Inc.'s Pulp & Paper division. From 1986 to 1990, he was Division Manager, S.D. Warren division of Scott Paper. Prior to that, he served as Production Manager for Buckeye Cellulose, a division of Proctor and Gamble, Inc. Mr. Kling received his B.S. degree in Civil Engineering from University of Alabama.

Daniel Michalopoulos, Ph.D . has been our Vice President, Marketing, Enzymes since January 2007. Prior to that he served as our Vice President, Pulp & Paper from February 2005 through December 2006 and is focused on growing our pulp and paper effort. Prior to joining us, he served as Senior Program Manager for Hercules' Pulp and Paper Division from 1998 to 2005 where he managed a staff of 40 people with an annual budget of $8 million. Prior to that, he served as Research Director at BetzDearborn Pulp and Paper Division and held other research and management positions at Betz PaperChem. Dr. Michalopoulos conducted his post-doctoral work at Rice University, received his Ph.D. in Chemistry from Colorado State University and his B.S. in Chemistry from Lowell Technological Institute.

Richard J. Berman was elected by the Board to serve as its non-executive Chairman in June 2007, having served as C.E.O. of the Company from January 2006-June 2007, and on the Board of Directors since 2002. Since 2001, Mr. Berman has served as a Director and/or Chairman of several public and private companies. Mr. Berman currently serves as Chairman of National Investment Managers, a public company in pension administration and investment management; Chairman of Candidate Resources, a private company delivering HR services over the web, and Chairman of Fortress Technology Systems (homeland security). Mr. Berman is a director of eight public companies: Dyadic International, Inc. (AMEX: DIL), Broadcaster, Inc. (OTC: BCSR.OB), Internet Commerce Corporation (Nasdaq: ICCA), MediaBay, Inc. (Nasdaq: MBAY), NexMed, Inc., National Investment Managers (OTC: NIVM.OB), Advaxis, Inc. (OTC: ADXS.OB), and NeoStem, Inc (OTC:NEOI.OB). He is a past Director of the Stern School of Business of NYU, where he obtained his BS and MBA. He has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.

Dr. Sinitsyn is a member of the Russian National Research Program on Enzyme Engineering Council. He has co-authored 270 publications in Russian and international scientific journals, as well as more than 20 Russian and three international patents. Dr. Sinitsyn received his Ph.D. in Enzymology and Dr. of Sciences in Enzymology and Biochemistry from Moscow State University.

Dr. Barbas is a Professor of The Scripps Research Institute, Departments of Molecular Biology and Chemistry and The Skaggs Institute for Chemical Biology. He holds the Janet and W. Keith Kellogg II endowed Chair in Molecular Biology and Chemistry. Dr. Barbas has received honours including the Investigator Award from the Cancer Research Institute, The Scholar Award of the American Foundation for AIDS Research, and the Presidential Green Chemistry Challenge Award. He is the author of over 200 scientific articles and is a named inventor on 32 issued U.S. patents. Key accomplishments in the area of biotechnology pioneered by Dr. Barbas and his colleagues include the development of the first human antibody phage libraries, development of the first synthetic antibodies, the development of the first artificial transcription factors capable of regulating endogenous genes, and chemically programmed antibodies-the CovX core technology. Dr. Barbas received his Ph.D. in Organic Chemistry from Texas A&M University.

Gerald R. Fink, Ph.D. is a founder of Microbia and a founding member and former director of Whitehead Institute for Biomedical Research, and is the American Cancer Society Professor of Genetics at Whitehead Institute/MIT. He is a member of the National Academy of Sciences and the Institute of Medicine. Dr. Fink is an international leader in the molecular genetics and cell biology of brewers' yeast and the fungal pathogen, Candida. He is a non-resident fellow of the Salk Institute, is on the scientific advisory boards of the Biozentrum in Basel and Dyadic Inc., and is also a member of the Medical Advisory Board of the Howard Hughes Medical Institute.

Dr. Peter J. Punt has been a staff scientist in molecular genetics at TNO Nutrition and Food Research Institute in the Netherlands since 1983. He has worked at TNO as a project leader since 1992 - and more recently as workgroup leader - in the department of Applied Microbiology and Gene Technology. Dr. Punt has co-authored more than 40 peer-reviewed scientific papers and three published patents. Dr. Punt obtained his M.Sc. in Biology from Leiden University in 1984, and his Ph.D. in Molecular Genetics from Amsterdam University in 1992. Head of Laboratory, Department of Enzymology, Moscow State University, Moscow, Russia Dr. Sinitsyn has worked with Moscow State University since 1974, first as a researcher, then as a senior researcher, and most recently as the head of its Laboratory of Physical Chemistry of Enzymatic Transformation of Polymers. His scientific expertise includes enzymology, biochemistry, microbiology, and genetics of carbohydrases (cellulases and xylanases), proteases, lipases, esterases, and other enzymes for application in textiles and detergents, pulp and paper, food and animal feed, and other industrial uses.